In 2021, we've seen positive clinical data for the first ever in vivo CRISPR medicines, base editors are heading for the clinic, and CRISPR therapies...
Base editors are derived from CRISPR-Cas technology and have the potential to cure many genetic diseases by precisely correcting single pathogenic...
The CRISPR gene-editing therapy more than doubled the lifespan in a mouse model by tackling the root cause of Hutchinson-Gilford progeria. The new...
